Please assess the completion status of the following clinical trial:

Trial Title: Is Vitamin D2 Treatment-associated Decrease in 25(OH)D3 Level a Reciprocal Phenomena?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* non-pregnant adults (age ≥18 years)~* healthy~* total 25(OH)D level between 20 to 65 nmol/L.~* living in Riyadh area~Exclusion criteria:~* consumption of more than one serving of milk daily~* taking vitamin D supplements~* habitual weekly sun exposure of 10 hours or more~* history of granulomatous, liver, or kidney disease~* taking anticonvulsants, barbiturates, or steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group-2-D3 (Type: EXPERIMENTAL): Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
- Group-2-Placebo (Type: PLACEBO_COMPARATOR): Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
- Group-1-D2 (Type: EXPERIMENTAL): Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
- Group-1-Placebo (Type: PLACEBO_COMPARATOR): Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).